

Montana Poison Center

SUD Strategic Taskforce Meeting: 7/19/23

Helena, Montana

Montana Poison Center Introductions

- Shireen Banerji, PharmD, Managing Director
- Christopher Hoyte, MD, Medical Director
- Brandon Ensign, MBA, Director, Med Info



What is Rocky Mountain Poison & Drug Safety (RMPDS)?





Rocky Mountain Poison Center Service Region



Montana Poison Center Overview

- One of the largest certified Poison Centers
- 24 x 7 service, 365 days
- Staffed by Specialists in Poison Information (SPI)
- Disaster Recovery System
- Core Competency
 - Medical Management of Poisonings/Exposures
- Caller Types
 - General public
 - Healthcare professionals
 - Persons in the workplace
 - Public Health
 - Law Enforcement
- Omni-channel capabilities (phone, SMS, web chat, email)

Montana Poison Center

Staff


- CSPI/SPI: [Certified] Specialists in Poison Information manage all healthcare and public exposure calls.
 - RNs, PharmDs (n=22)
 - 68% CSPI Staff as of July 2023
- PIP: Poison Information Providers manage low acuity calls
 - Para-professionals

Backup support


- Medical Toxicology (physician) fellows & board-certified Medical Toxicologists
- Clinical Toxicologists
- Medical Director



US Poison Center Total Case Volume: 2000-2022



Montana PC Case Volume: 2000-2022




Montana PC: 2022 Case Breakdown

Case Type	Number of cases
Exposures	7,446
Drug identification	110
Poison information	38
Caller Referred	56
Other information	22
Drug information	60
Administrative	1
Prevention / Safety / Education	6
Environmental information	5
Medical information	4
Occupational information	1



Montana PC: 2022 Exposures by County



Montana PC: 2022 Exposures by County

County	# Exposures
Beaverhead	52
Big Horn	93
Blaine	58
Broadwater	25
Carbon	64
Carter	9
Cascade	581
Chouteau	19
Custer	71
Daniels	6
Dawson	59
Deer Lodge	62
Fallon	19
Fergus	45
Flathead	<mark>783</mark>
Gallatin	723
Garfield	4
Glacier	156

County	# Exposures
Granite	14
Hill	142
Jefferson	47
Judith Basin	8
Lake	170
Lewis And Clark	516
Liberty	12
Lincoln	128
Madison	37
Mccone	5
Meagher	10
Mineral	44
Missoula Missoula	802
Musselshell	19
Park	106
Petroleum	4
Phillips	15
Pondera	29

County	# Exposures
Powder River	5
Powell	63
Prairie	4
Ravalli	295
Richland	48
Roosevelt	65
Rosebud	58
Sanders	61
Sheridan	19
Silver Bow	268
Stillwater	46
Sweet Grass	11
Teton	33
Toole	13
Treasure	4
Valley	39
Wheatland	21
Wibaux	2
Yellowstone	<mark>1,151</mark>

Top 10 Exposures Montana Poison Center 2022

Substance	% of Total		
Analgesics (OTC & Rx)	15.23		
Household cleaners	6.95		
Cosmetics/personal care	5.44		
Sedatives, hypnotics, antipsychotics	5.40		
Cardiovascular drugs	5.31		
Dietary supplements/herbals/ homeopathic remedies	4.34		
Alcohols	3.60		
Foreign bodies/toys	3.28		
Antihistamines	2.79		
Plants	2.77		



Top 10 Exposures (Age ≤ 5 yrs) Montana Poison Center 2022

Substance	% of Total		
Analgesics	14.13		
Cosmetics/personal care	9.33		
Household cleaners	9.02		
Dietary supplements/herbals/ homeopathic remedies	8.44		
Foreign bodies/toys	6.12		
Vitamins	4.99		
Topical preparations	4.44		
Plants	4.16		
Gastrointestinal preps	3.09		
Pesticides	2.66		




MT PC Exposures by Age, Gender: 2022

AGE	%
≤ 5 years	42.2
6 – 12 years	5.5
13 – 19 years	11
≥ 20 years	39
Unknown age	2.3

Female	Male
53.8	44.7



Montana PC: Exposure Reasons






Human Exposures: Medical Outcomes by Reason, Montana PC 2022

	Unintentional	Suspected Suicide	Abuse	% of Total
No Effect	4430	303	19	55.4
Minor Effect	1642	550	81	26.5
Moderate Effect	243	364	54	7.7
Major Effect	10	40	12	0.7
Death	0	1	1	0.02
Not followed	513	107	15	7.4
Unrelated Effect	153	18	1	2
Confirmed nonexposure	14	0	1	.02




Human Exposures: Disposition Montana PC 2022





Human Exposures: Level of Care Montana PC 2022





Montana 2022 Human Fatalities

Age	Gender	Reason	Route	Substance
1 <i>7</i> y	M	Abuse	Ingestion	Molly
39y	M	Intentional Misuse	Ingestion	Meth Oxycodone
72y	M	Suicide	Ingestion	Polydrug



2022 RMPC Data Summary: Montana

17.8% were suspected suicides.

10.5% resulted in serious outcomes. *

0.04% (3) resulted in death.

91.5% occurred at a residence.

60.5% were managed on site.

30.6% cases originated from a Health Care Facility.


* serious outcomes are defined as Moderate effect, Major effect, Death or Death, Indirect. **7199 Total**

Human

Exposures



Human Exposures: Drugs of Abuse Montana PC 2022





Human Exposures: Marijuana Montana PC 2022

- 51 Exposures (Age 0-5y = 19 exposures)
 - Disposition
 - Managed on site: 22%
 - Already in hospital when PC called: 61%
 - PC referred to hospital: 14%
 - Lost to follow-up: 4%
 - Outcomes
 - No effect: 27%
 - Minor effect: 41%
 - Moderate effect: 27%

- Major effect: 0
- Death: 0
- Lost to follow-up: 4%



Human Exposures: Marijuana type Montana PC 2022

- Marijuana flower (dried): 19
- Marijuana concentrate: 4
- Marijuana edibles: 22
- Marijuana unknown type: 1
- Cannabidiol (CBD): 4
- Marijuana e-cigarette: 1



Human Exposures: Rx Opioids Montana PC 2022

- 143 Exposures
 - Disposition
 - 131 managed in health care facility (91.6%)
 - 11 managed on site (7.7%)
 - Reason
 - Intentional: 92 (64.3%)
 - Unintentional: 47 (32.9%)
 - Unknown: 4 (2.8%)



Human Exposures: Rx Opioids Montana PC 2022

- Medical Outcomes
 - No effect: 25.2%
 - Moderate: 32.2%
 - Lost to follow-up: 2.1%

- Minor: 28.7%
- Major: 9.1%
- Death: 0.7%



Human Exposures: Rx Opioids Montana PC 2022

- Most frequent products reported
 - Hydrocodone (34) or oxycodone (15) +
 acetaminophen, oxycodone single ingredient
 (25), fentanyl (19), tramadol (17),
 buprenorphine (15), methadone (5)
- Naloxone given in 40 cases (28%)













GRANDMA'S DRUGS

Major local effort launched to educate seniors and stem flow of unused medications



Science Demonstration Served on Englishmen Proceedings Served



Toxidromes

- Opioid
- Anticholinergic
- Sympathomimetic
- Serotonergic
- Cholinergic Crisis












Case

- 12-year-old male presents to the ED after being found unresponsive and being brought in from a "pharm party". He is cyanotic, does not arouse to verbal or physical stimuli, has decreased bowel sounds, and miosis.
- HR 65 BP 97/63 RR 4 Temp 35.0°C
- Pulse ox 71%







Hint(s)

- China Waterhorse
- Hell dust
- Skag
- Apache
- King Ivory
- Tango and Cash






Opioids

- Respiratory depression
- CNS depression
- QT interval prolongation (methadone)
- Seizures (tramadol)
- Naloxone
- Intubation

















five (100 mcg/h) systems


Synthetic Fentanyl Derivatives

- Carfentenil
- Remifentanil
- Sufentanil
- Theft from veterinarian offices
- 10,000X more potent than morphine, 100X more potent than fentanyl
- Opioid toxicity
- Respiratory depression
- Death











Tranq Dope






Fentanyl

- analgesic
- mu opioid receptor agonist
- Rapid onset, short duration
- AMS, miosis, respiratory depression, decreased bowel sounds
- High addiction potential
- Current epidemic
- Patches, pills, liquid, lollipops

Xylazine

- Centrally acting α-2 receptor agonist (like clonidine)
- Veterinary medicine, large animal and game tranquilizer
- AMS (sedation), hypotension, bradycardia









Tranq Dope Mechanisms of Toxicity


Fentanyl



Xylazine









"Krokodil" and "Tranq Dope"







Isonitazene











Medication-Assisted Treatment



Sea

Find Treatment

Practitioner Training

Grants

Data

Programs

Ne



Medication-Assisted Treatment (MAT)

Medication-assisted treatment (MAT), including opioid treatment programs (OTPs), combines behavioral therapy and medications to treat substance use disorders.



Montana Poison Center, SUD



NALTREXONE(REVIA)





enorphine (Bup) Hospital Quick Start

riber can order Bup in the hospital, even without an x-waiver.

nigh-affinity, partial agonist opioid that is safe and highly effective for treating opioid use disorder. is stable on methadone or prefers methadone, recommend continuation of methadone as reatment.

Uncomplicated* opioid withdrawal?**

YES (stop other opioids)

Administer 8mg Bup SL



Withdrawal symptoms improved?



Administer 2nd dose

Inpatient: 8mg. Subsequent days, titrate from 16mg with additional 4-8mg pm cravings. ED: 8-24mg. Consider discharge with higher loading dose.

Maintenance Treatment 16 mg Bup SL/day

Titrate to suppress cravings; Usual total dose 16-32mg/day

Discharge

- Document Opioid Withdrawal and/or Opioid Use Disorder as a diagnosis.
- If no X-waiver: Use loading dose up to 32mg for long effect and give rapid follow up.
- If X-waiver: Check CURES (not required in Emergency Department if ≤7 day prescription), prescribe sufficient Bup/Nx until follow-up.

Start Bup after withdrawal

NO-

Supportive meds prn, stop other opioids

Buprenorphine Dosing

- Either Bup or Bup/Nx (buprenorphine/naloxone) films or tab sublingual (SL) are OK.
- . If unable to take oral/SL, try Bup 0.3mg IV/IM.
- . OK to start with lower initial dose: Bup 2-4mg SL.
- Total initial daily dose above 16mg may increase duration of action beyond 24 hrs.
- Bup SL onset 15 min, peak 1 hr, steady state 7 days
- May dose qday or if co-exisiting chronic pain split dosing TID/QID.

No laproden C Differential Diagnosis:

 Withdrawal mimic: Influenza, DKA, sepsis, thyrotoxicosis, etc. Treat underlyling illness.

• Ind. up Below Ged with the Company of the Company

- Bup side-effect: Nausea, headache, dysphoria. Continue Bup, treat symptoms with supportive medications.
- · Precipitated withdrawal:

Too large a dose started too soon after opioid agonist.

Usually time limited, self resolving with supportive medications.

In complex or severe cases of precipitated withdrawal, OK to stop Bup and give short acting full antagonists.

*Complicating Factors Very a set of a true of the argument of

**Diagnosing Opioid Withdrawal
Subjective symptoms AND one objective sign

subjective: Patient reports feeling additions to withdrawal (nausea, stomach cram and proches et al., 1997). The crim and the stomach cram and proches et al., 1997, 199

rhinorrhea, dilated pupils, watery eyes, tachycardia, yawning, goose bumps, vomiting, diarrhea, tremor

Typical withdrawal onset:

- ≥ 12 hrs after short acting opioid
- ≥ 24 hrs after long acting opioid
- ≥ 48 hrs after methadone (can be >72 hrs)

If unsure, use COWS (clinical opioid withdrawal scale). Start if COWS \geq 8 AND one objective sign.

If Completed Withdrawal:

Typically >72 hrs since last short-acting opioid, may be longer for methadone. Start Bup 4mg q4h pm cravings, usual dose 16-32mg/day. Subsequent days, OK to decrease frequency to qday

Opioid Analgesics

- Pause opioid pain relievers when starting Bup.
- OK to introduce opioid pain relievers after Bup is started for breakthrough pain. Do not use methadone with Bup.

Supportive Medications

Can be used as needed while waiting for withdrawal
 Auring industries process.



Referral for follow-up





mHealth






RMPC supports Drug Take Back Programs







Telemedicine





Mobile Devices







Naloxone in Schools







Benefits

- Health Outcomes
 - Individual
 - Population
- Costs
- Access



Thank you

